<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02573597</url>
  </required_header>
  <id_info>
    <org_study_id>34734</org_study_id>
    <nct_id>NCT02573597</nct_id>
  </id_info>
  <brief_title>PIEB vs CEI for Labor Analgesia: An MLAC Study</brief_title>
  <official_title>Programmed Intermittent Epidural Bolus (PIEB) Compared to Continuous Epidural Infusion (CEI) Relative Efficacy and Mechanism of Efficacy For Labor Anlagesia: A Minimal Local Analgesic Concentration (MLAC) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Manchester University NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Utilizing a 'minimal local analgesic concentration (MLAC) study' design to first determine&#xD;
      the relative potency of Programmed Intermittent Epidural Bolus (PIEB) compared to Continuous&#xD;
      Epidural Infusion (CEI) and secondly to determine the mechanism to explain the potential PIEB&#xD;
      efficacy advantage.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pregnant women who present to Labor and Delivery for an anticipated vaginal delivery will be&#xD;
      identified as potential participants based on inclusion/exclusion criteria and their desire&#xD;
      for labor epidural analgesia. Once identified, interested candidates will be fully informed&#xD;
      of the study procedures, have all questions answered, and informed consent obtained. Pregnant&#xD;
      participants will receive a labor epidural upon the patient's request and dosed per protocol&#xD;
      to adequate analgesic level.&#xD;
&#xD;
      Patients will be randomized into 1 of 4 groups. Either group I or II in Study Part A and&#xD;
      group III or IV in Study Part B in a double-blinded design. Each study part will run in&#xD;
      parallel and independently.&#xD;
&#xD;
      Each group will have a varying concentration of bupivicaine infusion; continuous or&#xD;
      intermittent bolus administration. In addition each group will have continuous or&#xD;
      intermittent bolus administration of sufentanil. These concentrations and forms of&#xD;
      administration will be blinded to both the patient and study administrator.&#xD;
&#xD;
      Each epidural infusion concentration and continuous or bolus administration will be&#xD;
      determined to be a success or failure based on analgesic scores. The investigators' primary&#xD;
      outcome will be the minimal local anesthetic concentration of the final participants in each&#xD;
      respective group upon study completion.&#xD;
&#xD;
      DATA SAFETY MONITORING PLAN will follow standard of clinical care. Any adverse events will be&#xD;
      reported to the PI and necessary adjustments to the protocol will be immediately instituted.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MLAC of the final participants in each respective group at study completion</measure>
    <time_frame>approximately 6-12 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first clinician rescue analgesia request (from initial epidural dose)</measure>
    <time_frame>approximately 6-12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numerical verbal pain scores</measure>
    <time_frame>approximately 6-12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction with labor analgesia</measure>
    <time_frame>approximately 6-12 hours</time_frame>
    <description>0-100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of epidural analgesia</measure>
    <time_frame>approximately 6-12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Labor outcome (spontaneous, assisted, cesarean)</measure>
    <time_frame>approximately 6-12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requests to turn epidural down or stop infusion.</measure>
    <time_frame>approximately 6-12 hours</time_frame>
    <description>yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total CEI and PIEB local anesthetic and opioid use</measure>
    <time_frame>approximately 6-12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and total dose of clinician rescue boluses</measure>
    <time_frame>approximately 6-12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor weakness</measure>
    <time_frame>approximately 6-12 hours</time_frame>
    <description>Straight leg lift, yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal pruritis</measure>
    <time_frame>approximately 6-12 hours</time_frame>
    <description>scale from from 0-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment for pruritus, nausea and vomiting, and hypotension</measure>
    <time_frame>approximately 6-12 hours</time_frame>
    <description>yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal nausea/vomiting</measure>
    <time_frame>6-12 hours</time_frame>
    <description>yes/no</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Part A Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CEI bupivacaine and CEI sufentanil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PIEB bupivacaine and PIEB sufentanil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CEI bupivacaine and PIEB sufentanil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Group 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PIEB bupivacaine and CEI sufentanil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>Continuous or bolus administration</description>
    <arm_group_label>Part A Group 1</arm_group_label>
    <arm_group_label>Part A Group 2</arm_group_label>
    <arm_group_label>Part B Group 3</arm_group_label>
    <arm_group_label>Part B Group 4</arm_group_label>
    <other_name>marcaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sufentanil</intervention_name>
    <description>Continuous or bolus administration</description>
    <arm_group_label>Part A Group 1</arm_group_label>
    <arm_group_label>Part A Group 2</arm_group_label>
    <arm_group_label>Part B Group 3</arm_group_label>
    <arm_group_label>Part B Group 4</arm_group_label>
    <other_name>sufenta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA I &amp; II, Nulliparous and Multiparous, Spontaneous/Induced/Augmented Labor, Early&#xD;
             active labor (cervix &lt;5 cm (if known)), Pain (VPS) &gt; 3, 18-45 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt;37 weeks gestation, H/o Cesarean Section, Multiple Gestation, Pre-eclampsia,&#xD;
             Narcotics within 3 hours prior to labor epidural placement, Chronic Pain (as defined&#xD;
             by chronic opiate consumption), Women who are participating in another study that will&#xD;
             impact protocol&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brendan Carvalho, MBBCh, MDCH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brendan Carvalho, MBBCh, MDCH</last_name>
    <phone>(650) 724-2614</phone>
    <email>bcarvalho@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ed Riley, MD</last_name>
    <phone>(650) 723-6411</phone>
    <email>edriley@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aramina Aksamit, RN</last_name>
      <phone>512-287-0594</phone>
      <email>aramina.a@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>George RB, Allen TK, Habib AS. Intermittent epidural bolus compared with continuous epidural infusions for labor analgesia: a systematic review and meta-analysis. Anesth Analg. 2013 Jan;116(1):133-44. doi: 10.1213/ANE.0b013e3182713b26. Epub 2012 Dec 7. Review. Erratum in: Anesth Analg. 2013 Jun;116(6):1385.</citation>
    <PMID>23223119</PMID>
  </reference>
  <reference>
    <citation>Ginosar Y, Columb MO, Cohen SE, Mirikatani E, Tingle MS, Ratner EF, Angst MS, Riley ET. The site of action of epidural fentanyl infusions in the presence of local anesthetics: a minimum local analgesic concentration infusion study in nulliparous labor. Anesth Analg. 2003 Nov;97(5):1439-1445. doi: 10.1213/01.ANE.0000081792.84877.A2.</citation>
    <PMID>14570662</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 25, 2015</study_first_submitted>
  <study_first_submitted_qc>October 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2015</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Brendan Carvalho</investigator_full_name>
    <investigator_title>Chief, Division of Obstetric Anesthesia Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sufentanil</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

